A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients

Jørn Herrstedt, J Huober, F Priou, HH Müller, M Baekelandt, C Kurzeder, J Pfisterer, A Stähle, I Ray-Coquard, A du Bois

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

OriginalsprogEngelsk
Publikationsdato2009
StatusUdgivet - 2009
BegivenhedMeeting ASCO - Orlando, USA
Varighed: 29. maj 20092. jun. 2009
Konferencens nummer: 45

Konference

KonferenceMeeting ASCO
Nummer45
LandUSA
ByOrlando
Periode29/05/200902/06/2009

Citer dette

Herrstedt, Jørn ; Huober, J ; Priou, F ; Müller, HH ; Baekelandt, M ; Kurzeder, C ; Pfisterer, J ; Stähle, A ; Ray-Coquard, I ; du Bois, A. / A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients. Abstract fra Meeting ASCO, Orlando, USA.
@conference{48b9f2c0fe9d11deaefb000ea68e967b,
title = "A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients",
author = "J{\o}rn Herrstedt and J Huober and F Priou and HH M{\"u}ller and M Baekelandt and C Kurzeder and J Pfisterer and A St{\"a}hle and I Ray-Coquard and {du Bois}, A",
year = "2009",
language = "English",
note = "null ; Conference date: 29-05-2009 Through 02-06-2009",

}

Herrstedt, J, Huober, J, Priou, F, Müller, HH, Baekelandt, M, Kurzeder, C, Pfisterer, J, Stähle, A, Ray-Coquard, I & du Bois, A 2009, 'A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients', Meeting ASCO, Orlando, USA, 29/05/2009 - 02/06/2009.

A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients. / Herrstedt, Jørn; Huober, J; Priou, F; Müller, HH; Baekelandt, M; Kurzeder, C; Pfisterer, J; Stähle, A; Ray-Coquard, I; du Bois, A.

2009. Abstract fra Meeting ASCO, Orlando, USA.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

TY - ABST

T1 - A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients

AU - Herrstedt, Jørn

AU - Huober, J

AU - Priou, F

AU - Müller, HH

AU - Baekelandt, M

AU - Kurzeder, C

AU - Pfisterer, J

AU - Stähle, A

AU - Ray-Coquard, I

AU - du Bois, A

PY - 2009

Y1 - 2009

M3 - Conference abstract for conference

ER -